[go: up one dir, main page]

WO2012170452A3 - Compositions and methods for treating neurodegenerative diseases - Google Patents

Compositions and methods for treating neurodegenerative diseases Download PDF

Info

Publication number
WO2012170452A3
WO2012170452A3 PCT/US2012/040970 US2012040970W WO2012170452A3 WO 2012170452 A3 WO2012170452 A3 WO 2012170452A3 US 2012040970 W US2012040970 W US 2012040970W WO 2012170452 A3 WO2012170452 A3 WO 2012170452A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating neurodegenerative
neurodegenerative diseases
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/040970
Other languages
French (fr)
Other versions
WO2012170452A2 (en
Inventor
Chengbiao Wu
William C. Mobley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2012170452A2 publication Critical patent/WO2012170452A2/en
Publication of WO2012170452A3 publication Critical patent/WO2012170452A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods and compositions for treating neurodegenerative disorders without pain associated with traditional treatments by administering a nerve growth factor (NGF) mutein. The invention also provides methods and compositions for treating pain in a subject.
PCT/US2012/040970 2011-06-06 2012-06-06 Compositions and methods for treating neurodegenerative diseases Ceased WO2012170452A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493879P 2011-06-06 2011-06-06
US61/493,879 2011-06-06

Publications (2)

Publication Number Publication Date
WO2012170452A2 WO2012170452A2 (en) 2012-12-13
WO2012170452A3 true WO2012170452A3 (en) 2013-04-04

Family

ID=47296701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/040970 Ceased WO2012170452A2 (en) 2011-06-06 2012-06-06 Compositions and methods for treating neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2012170452A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20161364A1 (en) * 2016-03-04 2017-09-04 Antonino Cattaneo TNF ALPHA ASTROCITARY INHIBITOR FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES.
US20230287072A1 (en) * 2020-08-04 2023-09-14 The Regents Of The University Of California Composition and method for treating neuropathy
CN114933657B (en) * 2021-08-25 2024-02-02 上海交通大学医学院 Nerve growth factor mutant recombinant protein and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033447A1 (en) * 2005-04-11 2011-02-10 Arnon Rosenthal Methods for Treating Osteoarthritis Pain By Administering a Nerve Growth Factor Antagonist and Compositions Containing the Same
US20110082285A1 (en) * 2007-03-07 2011-04-07 Staidson (Beijing) Pharmaceutical Co., Ltd Transgenic rodents having ngf beta gene mutants and its preparation methods, the preparation methods of the corresponding mutant proteins and the resulting mutant proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033447A1 (en) * 2005-04-11 2011-02-10 Arnon Rosenthal Methods for Treating Osteoarthritis Pain By Administering a Nerve Growth Factor Antagonist and Compositions Containing the Same
US20110082285A1 (en) * 2007-03-07 2011-04-07 Staidson (Beijing) Pharmaceutical Co., Ltd Transgenic rodents having ngf beta gene mutants and its preparation methods, the preparation methods of the corresponding mutant proteins and the resulting mutant proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMONA CAPSONI ET AL.: "Taking Pain Out of NGF: A ''Painless'' NGF Mutant, Linked to Hereditary Sensory Autonomic Neuropathy Type V, with Full Neurotrophic Activity", PLOS ONE, vol. 6, no. 2, February 2011 (2011-02-01), pages 217321 *

Also Published As

Publication number Publication date
WO2012170452A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012062925A3 (en) Compounds and methods for treating pain
WO2013061161A3 (en) New combination therapies for treating neurological disorders
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2022004300A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
EA201590870A1 (en) AMINO-SUBSTITUTED IMIDAZO [1,2-a] Pyridinecarboxamides and their use
MX346224B (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
WO2014012094A3 (en) Tetracycline compounds for treating neurodegenerative disorders
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
PL2726470T3 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
DK2714888T3 (en) RECOMBINANT DO
WO2013098416A3 (en) Pain relief compounds
WO2012027326A9 (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2014153385A3 (en) Methods of treating metabolic disorders
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2013015347A (en) Egfr targeted therapy.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
WO2012170452A3 (en) Compositions and methods for treating neurodegenerative diseases
MX2015005111A (en) Herbal composition for the prevention and treatment of tnf-î± mediated diseases.
WO2014008118A3 (en) Method for concurrent treatment of pain and depression
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
WO2014062870A3 (en) Treatment of brain injury or trauma with tsg-6 protein
HK1209051A1 (en) A method of improving liver function
MX364232B (en) Baclofen and acamprosate based therapy of macular degeneration disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12796212

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12796212

Country of ref document: EP

Kind code of ref document: A2